Teva Pharmaceutical Industries Stock Shares Outstanding
TEVA Stock | ILA 4,885 25.00 0.51% |
Teva Pharmaceutical Industries fundamentals help investors to digest information that contributes to Teva Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Teva Stock. The fundamental analysis module provides a way to measure Teva Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Teva Pharmaceutical stock.
Teva |
Teva Pharmaceutical Industries Company Shares Outstanding Analysis
Teva Pharmaceutical's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Teva Pharmaceutical Shares Outstanding | 1.11 B |
Most of Teva Pharmaceutical's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Teva Pharmaceutical Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition |
Based on the latest financial disclosure, Teva Pharmaceutical Industries has 1.11 B of shares currently outstending. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The shares outstanding for all Israel stocks is 94.27% lower than that of the firm.
Did you try this?
Run USA ETFs Now
USA ETFsFind actively traded Exchange Traded Funds (ETF) in USA |
All Next | Launch Module |
Teva Fundamentals
Return On Equity | -0.24 | |||
Return On Asset | 0.0363 | |||
Profit Margin | (0.16) % | |||
Operating Margin | 0.18 % | |||
Current Valuation | 102.13 B | |||
Shares Outstanding | 1.11 B | |||
Shares Owned By Insiders | 0.77 % | |||
Shares Owned By Institutions | 5.30 % | |||
Price To Book | 1.18 X | |||
Price To Sales | 2.32 X | |||
Revenue | 14.93 B | |||
Gross Profit | 6.97 B | |||
EBITDA | (791 M) | |||
Net Income | (2.35 B) | |||
Cash And Equivalents | 2.44 B | |||
Cash Per Share | 2.21 X | |||
Total Debt | 19.1 B | |||
Debt To Equity | 2.26 % | |||
Current Ratio | 1.01 X | |||
Book Value Per Share | 7.11 X | |||
Cash Flow From Operations | 1.59 B | |||
Earnings Per Share | (0.56) X | |||
Price To Earnings To Growth | 0.67 X | |||
Target Price | 11.0 | |||
Number Of Employees | 34 K | |||
Beta | 1.22 | |||
Market Capitalization | 39.95 B | |||
Total Asset | 44.01 B | |||
Retained Earnings | 14.99 B | |||
Working Capital | 5.39 B | |||
Current Asset | 18.4 B | |||
Current Liabilities | 13.01 B | |||
Z Score | 1.2 | |||
Five Year Return | 2.96 % | |||
Net Asset | 44.01 B |
About Teva Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Teva Pharmaceutical Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Teva Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Teva Pharmaceutical Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharmaceutical Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Teva Stock analysis
When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |